Azitra has amended its Phase 1/2 trial for ATR04-484 to include patients with skin rashes caused by KRAS and MEK inhibitors, in addition to those with EGFR inhibitor-related rashes. This expansion also covers patients with neurofibromatosis type 1 (NF1) experiencing MEK inhibitor-associated rash, broadening the potential treatment population significantly. The changes, including shorter washout periods for antibiotics and steroids, aim to facilitate faster patient recruitment and accelerate trial enrollment. ATR04-484 is a live biotherapeutic targeting inflammatory skin rashes linked to cancer treatments, with Fast Track FDA designation recognizing its potential to address a high unmet medical need.
Azitra, Inc.'s clinical trial expansion is presented here with Health-sector market context from Pluang as of Oct 29, 2026 19:12 WIB: Among 150 priced US Health stocks, 91 rose and 53 fell. NUWE surged 27.04% to USD 7.07 with a typical hold time of 29 days, contrasting with IOVA's 25.79% drop to USD 10.99 and a very short 5-day hold time. MESO also gained 18.22% to USD 15.83, held typically for 17 days on Pluang.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
